This FREE webcast series gives you direct access to companies that have the potential to be the next big thing – it’s an ideal platform for you to identify fast growing, high value opportunities.
Wednesday, 21st October 12pm (AEDT)
Each session features a selection of CEOs who provide a succinct overview of big things their companies are doing, followed by an interactive Q&A.
This week we are joined by:
- (ASX: TD1) TALi Digital Limited – Glenn Smith, Managing Director
- (ASX: TNT) Tesserent Limited – Julian Challingsworth, Chief Executive Officer
- (ASX: ATX) Amplia Therapeutics – Dr John Lambert, Chief Executive Officer
Managing Director - TALi Digital Limited (ASX: TD1)
TALi Digital (ASX: TD1) is an Australian Medical Technology Company seeking to improve attention in early childhood through its breakthrough TALi platform. TALi combines evidence-based proprietary algorithms inside a game-based program to assess and strengthen core attention skills.
Chief Executive Officer -Tesserent Limited (ASX: TNT)
Tesserent (ASX: TNT) is Australia’s largest ASX listed cybersecurity provider, is on track to deliver on our strategy to provide clients with a full suite of cybersecurity services: Cyber 360. The company’s Cyber 360 strategy delivers integrated solutions covering identification, protection and 24/7 monitoring against cyber security threats. With in excess of 220 security engineers, Tesserent has the capability to support organisations in defending their digital assets against increasing risks and cyber attacks.
Dr John Lambert
Chief Executive Officer - Amplia Therapeutics (ASX: ATX)
Amplia Therapeutics (ASX: ATX) is an Australian pharmaceutical company developing new drugs for cancer and fibrosis. The drugs target a protein called Focal Adhesion Kinase (FAK) which is an increasingly important target in cancer biology. Amplia has a particular product development focus in pancreatic and ovarian cancer as well as life-threatening chronic diseases, such as idiopathic pulmonary fibrosis (IPF). The company recently announced the initiation of clinical trials of its lead candidate, AMP945.